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Abstract
Background:  Although much progress has been made on antipsychotic drug development,
precise mechanisms behind the action of typical and atypical antipsychotics are poorly understood.
Methods:  We performed genome-wide expression profiling to study effects of typical
antipsychotics and atypical antipsychotics in the postmortem liver of schizophrenia patients using
microarrays (Affymetrix U133 plus2.0). We classified the subjects into typical antipsychotics (n =
24) or atypical antipsychotics (n = 26) based on their medication history, and compared gene
expression profiles with unaffected controls (n = 34). We further analyzed individual antipsychotic
effects on gene expression by sub-classifying the subjects into four major antipsychotic groups
including haloperidol, phenothiazines, olanzapine and risperidone.
Results: Typical antipsychotics affected genes associated with nuclear protein, stress responses
and phosphorylation, whereas atypical antipsychotics affected genes associated with golgi/
endoplasmic reticulum and cytoplasm transport. Comparison between typical antipsychotics and
atypical antipsychotics further identified genes associated with lipid metabolism and mitochondrial
function. Analyses on individual antipsychotics revealed a set of genes (151 transcripts, FDR
adjusted p < 0.05) that are differentially regulated by four antipsychotics, particularly by
phenothiazines, in the liver of schizophrenia patients.
Conclusion: Typical antipsychotics and atypical antipsychotics affect different genes and biological
function in the liver. Typical antipsychotic phenothiazines exert robust effects on gene expression
in the liver that may lead to liver toxicity. The genes found in the current study may benefit
antipsychotic drug development with better therapeutic and side effect profiles.
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Background
Differential therapeutic and side effects of typical antipsy-
chotic (AP) and atypical AP drugs in schizophrenia have
been documented [1,2]. Typical APs such as haloperidol
and phenothiazines induce elevation of serum prolactin,
extrapyramidal symptoms and tardive dyskinesia,
whereas atypical APs such as clozapine and olanzapine
induce metabolic syndromes and elevation of liver
enzyme levels [3-6]. However, precise mechanisms under-
lying the effects of typical and atypical AP drugs on gene
expression in the postmortem liver of schizophrenia
patients are poorly understood. Unlike typical APs, atypi-
cal APs appear to increase liver enzyme function although
they induce less hepatotoxicity [7-9]. The atypical AP drug
clozapine induces a metabolic syndrome by down-regu-
lating cytochrome P450 (CYP450) isozymes and by caus-
ing an accumulation of fatty acids in the liver [10].
However, certain typical APs, including chlorpromazine
and haloperidol, may also decrease the activity of CYP450
isozymes in the liver of rats [11,12]. While the effects of
APs on liver function have been confirmed in individuals
with schizophrenia, additional pharmacological and clin-
ical factors could also contribute to altered liver function
[13]. Interestingly, a study suggested that the metabolic
alterations leading to oxidative stress in the liver of schiz-
ophrenia patients may actually be linked to the disease
process itself [14].
Previous postmortem brain studies identified gene expres-
sion changes in metabolism-related pathways in schizo-
phrenia [15,16]. However, other studies found that AP
medication may act to compensate for the underlying
pathological deficits in the metabolic pathways in schizo-
phrenia [17,18]. For instance, genes involved in lipid
metabolism and cellular signaling are altered in the mice
brains by chronic AP treatment [19], suggesting that the
metabolic abnormalities may also be a function of the AP
medication. In schizophrenia, abnormal myelination and
oligodendrocytes have been described [20] and both typ-
ical and atypical APs may regulate the expression of genes
associated with lipid biosynthesis and myelination in cul-
tured human glioma cells [21]. Interestingly, these genes
are controlled by the sterol regulatory element-binding
protein (SREBP) transcription factors. Thus, SREBP-medi-
ated increase in glial cell lipogenesis could be one of the
potential mechanisms behind the AP medication. Also,
genes associated with cell cycle, intracellular signaling,
oxidative stress and metabolic functions are altered in the
lymphocytes of schizophrenia patients compared to nor-
mal controls [22]. However, this study identified the
schizophrenia subjects as medicated, minimally medi-
cated and un-medicated, so that it is difficult to interpret
which AP class affected those genes. In the human liver tis-
sues, typical APs and atypical APs may mediate different
functions leading to liver toxicity in schizophrenia
patients who had taken typical APs [23]. However, atypi-
cal AP treatment may increase levels of liver enzymes such
as alanine aminotransfeaminotransferase (ALT), aspartate
aminotransferase (AST), gamma-glutamyl transferase
(GGT), and alkaline phosphotase (ALP) [7]. Taken
together, these studies suggest that typical APs may cause
liver toxicity whereas atypical APs may regulate liver
enzyme functions. To our knowledge, the effects of differ-
ent APs on genome-wide expression profiles in the post-
mortem liver of schizophrenia patients have not been
reported.
Given the various effects of APs on genes and biological
functions in different tissues, we investigated the effects of
typical APs and atypical APs on gene expression profiles in
the postmortem liver of schizophrenia patients. We classi-
fied the schizophrenia subjects into either typical AP
group or atypical AP group based on their medication his-
tory from one or two years prior to death, and compared
gene expression profiles with unaffected controls. We fur-
ther analyzed individual AP medication effects on gene
expression by sub-classifying the subjects into four major




Postmortem liver tissues were obtained from the Stanley
Medical Research Institute (SMRI). The details of the post-
mortem tissue collection have been described previously
[24]. Information on medication was taken from the clin-
ical and the medical records, reviewed in each case. The
postmortem tissues were collected between 1995 and
2005 during the period when the use of typical AP medi-
cation was decreasing and the use of atypical AP medica-
tion was increasing. Thus, individual patients at the time
of death were being treated with typical or atypical AP
drugs. For quality of the tissue, exclusion criteria included:
age>65 years, poor quality RNA, and significant structural
pathology of the liver on postmortem examination. Sam-
ples were matched for age, gender, race, pH and total RNA
quality. Total RNA quality was determined by the Bioana-
lyzer 2100 electrophoresis system (Agilent Technologies,
Foster City, CA, USA) using RNA Integrity Number (RIN)
as previously described [25]. The schizophrenia subjects
were classified into two groups: those who had taken pre-
dominantly typical APs (phenothiazines, thioxanthenes,
butyrophenones, and diphenylbutylpiperidines) and
those who had taken predominantly atypical APs (clozap-
ine, risperidone, olanzapine, quetiapine, and aripipra-
zole). The brain collection protocol was reviewed and
approved by the SMRI. Detailed information on ethical
approval can be found at http://www.stanleyresearch.org.BMC Psychiatry 2009, 9:57 http://www.biomedcentral.com/1471-244X/9/57
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Microarray experiment
Frozen postmortem liver tissue was homogenized in Tri-
zol (Invitrogen, Carlsbad, CA), and the RNA was sepa-
rated with chloroform and high-speed centrifugation.
RNA was precipitated with isopropyl alcohol and washed
with 70% ethanol and the pellets of RNA were resus-
pended in DEPC water [25]. An additional step of RNeasy
column purification (Qiagen, Valencia, CA) was added to
increase the efficiency of RNA quantification and purity. A
genome-wide expression microarray experiment was car-
ried out using the Affymetrix chips (HG-U133 plus2.0,
54,675 transcripts) at the Microarray Core Facility of the
Johns Hopkins University (Baltimore, MD). Microarray
data including cel files, normalized data and demographic
information can be found at the Stanley Online Genomics
Database (https://www.stanleygenomics.org, Study id:
19).
Quality control of microarrays
The Affymetrix Microarray Analysis Suite 5.0 (MAS 5.0)
expression values were calculated based on scaling to a
target intensity of 100, then transformed by log2 (x+20).
Absent/Present calls were computed using the MAS 5.0
algorithm. The Absent/Present call rate was used for gene
filtering prior to the data analysis. All analysis was con-
ducted using the R statistical environment (R Develop-
ment Core Team (2007). R: A language and environment
for statistical computing. R Foundation for Statistical
Computing, Vienna, Austria). For the quality control
(QC) analysis, several primary QC metrics were used
including: scale factor, percent present, number of probes
with perfect match>mis-match, 5'/3' GAPDH, 5'/3' Actin
and average correlation. For each metric, we computed the
distribution of the metric across the samples within each
study. Although no hard cutoffs were applied for each of
the QC metrics, we examined the distribution of the met-
rics to determine whether samples appeared to be outliers
as described previously [26-29].
Demographic and clinical variable analyses
Each demographic and clinical variable was assessed
using regression analysis. The percentage of regulated
probes in each variable was calculated based on the crite-
ria of significance (p < 0.001 and fold change >1.3). For
the comparison of effect sizes, all demographics were ana-
lyzed using two levels. Continuous variables and ordered
categorical variables were cut at median values for the
regression analysis. Demographic factors were assessed
using all samples including those from the unaffected
controls, and the typical and atypical AP groups. Schizo-
phrenia-specific variables were analyzed only in schizo-
phrenia cases to avoid the confounding of demographic
effects and disease effects. The following demographic
and clinical variables were considered for all subjects: age,
gender, postmortem interval (PMI), body mass index
(BMI), pH, mRNA quality, heavy alcohol use, heavy drug
use and rate of death. The following clinical variables were
considered for the subjects with schizophrenia: global
severity of disease, suicide status, exacerbation of disease
at the time of death, insight, and duration of illness. Glo-
bal severity of disease is an estimate of the severity of ill-
ness for the entire course of illness. All schizophrenia
patients were rated against others. This assessment
includes both symptom severity and social disability.
Exacerbation of disease is an estimate of whether the per-
son's symptoms were getting worse at the time of death.
Heavy drug and alcohol use reflect substance abuse in the
past and at time of death. Insight is an assessment of the
individual's awareness of his/her illness. The assessment is
based on the medical records or from the family about
whether the individual voluntarily sought treatment and
complied with medication.
Antipsychotic medication analysis
Demographic and clinical variable analyses revealed sev-
eral confounding variables affecting expression of a signif-
icant number of genes in the liver (refrigerator time, PMI,
rate of death, RNA quality, heavy drug use, heavy alcohol
use, gender and suicide). Therefore, these confounding
variables were adjusted for AP class analysis in a series of
linear regression models, one model for each gene,
including typical or atypical AP drugs and eight confound-
ing variables as covariates and gene expression intensity
(log2 scale) as the dependent variable. The criteria of sig-
nificance for each gene were FC >1.3 and p < 0.001 after
adjusting for the confounding variables.
Following the AP class comparisons, individual AP drug
effects on gene expression in the liver were investigated.
Based on the recent medication history (one or two years
prior to death), the subjects were sub-classified into four
individual AP drug groups including phenothiazines (n =
12), haloperidol (n = 9), olanzapine (n = 11) and risperi-
done (n = 10). Schizophrenia subjects (n = 8) who had
taken both typical and atypical AP drugs during this
period were excluded. Individual AP drug comparisons
were performed using a single factor ANOVA to identify
genes that are differentially expressed among the AP drug
groups (FDR adjusted p < 0.05). The results from individ-
ual AP drug analysis were compared with the results from
AP class comparisons (multiple regression analyses) to
identify common set of genes between the two analyses.
Bioinformatic mappings
The NCBI's Database for Annotation, Visualization and
Integrated Discovery (DAVID, http://
david.abcc.ncifcrf.gov) was used as the standard source for
gene annotation information [30]. In the DAVID annota-
tion system, the Fisher's Exact test was used to measure the
gene-enrichment in annotation terms. The primary fieldsBMC Psychiatry 2009, 9:57 http://www.biomedcentral.com/1471-244X/9/57
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extracted from the DAVID include Entrez Gene ID, gene
symbol and gene summary. Additional annotations
included gene product mappings to the Gene Ontology
Consortium (GO) for GO terms.
Quantitative PCR
Total RNA was extracted from the postmortem liver tissue,
and the quality of RNA was assessed with the Bioanalyzer
2100 (Agilent, Foster City, CA). RNA was further purified
with the PureLink Micro to Midi Total RNA Purification
System (Invitrogen, Carlsbad, CA), and cDNA was synthe-
sized with RT-PCR using oligo dT primers. Using a 384-
well format with the ABI Prism 7900HT real-time detec-
tor, 1 μl aliquots of QuantiTect SYBR primer (20×), 10 μl
QPCR PCR Master mix (Applied Biosystems, Foster City,
CA), and 10 μl diluted cDNA were mixed together and
pipetted into single wells of the qPCR plate. Water was
added instead of cDNA in the no template controls (NTC)
for each gene tested. Thermo cycle conditions were: (1) 1
cycle for 2 min at 50°C, (2) 1 cycle for 15 min at 95°C,
and (3) 40 cycles for 15 sec at 95°C and 1 min at 60°C
and fluorescence was measured during the 60°C step for
each cycle as recommended by the manufacturer. Target
genes include ATP-binding cassette, sub-family G, mem-
ber 5 (ABCG5, NM_022436, QT00023415), androgen
receptor 1 (AR1, NM_005650, QT00076615), CCAAT/
enhancer binding protein, alpha (CEBPA, (NM_004364,
QT00203357), cytochrome P450, family 51, subfamily A,
polypeptide 1 (CYP51A1, NM_000786, QT00055790),
cytochrome P450, family 7, subfamily A, polypeptide 1
(CYP7A1, NM_000780, QT00001085), FOS-like antigen
2 (FOSL2, NM_005253, QT01000881), interleukin 1
receptor antagonist (IL1RN, NM_173843, QT01002918)
and superoxide dismutase 2 (SOD2, NM_000636,
QT01008693). Three endogenous control genes were
selected for the qPCR experiment: β-2 microglobulin
(B2M, NM_004048, QT00088935), glyceraldehyde-3-
phosphate dehydrogenase (GAPDH, NM_002046,
QT01192646) and β-actin (ACTB, NM_001101,
QT00095431). Polymerase chain reactions were quanti-
fied by the relative ΔΔCt method using the SDS2.2 soft-
ware (Applied Biosystems, Foster City, CA). An average Ct
value for each sample from the triplicates of that sample
was calculated for each gene. Geometric mean of three
endogenous control genes (B2M, ACTB and GAPDH) was
used to normalize the data for each gene of interest. The
normalized values for each gene of interest in the typical
AP class were expressed as fold change (FC) as compared
to the atypical AP class.
Results
Table 1 shows a summary of subject characteristics with
demographic and clinical variables. Demographic varia-
bles such as age, gender, race and BMI are matched
between the controls, the typical AP and the atypical AP
group. Both typical and atypical AP groups had a higher
incidence of suicide and a longer PMI compared to the
control group. Subsequent analysis on individual varia-
bles revealed that suicide and PMI affected expression of a
significant number of genes. Thus, these variables were
adjusted in the AP medication analysis using the multiple
regression models.
Demographic and clinical variable analyses identified
potential confounding variables affecting the expression
of a significant number of transcripts in the postmortem
liver (Figure 1). Three variables including refrigerator
time, PMI and rate of death affected more than 1% of the
transcripts based on the significant criteria of fold change
>1.3 and p < 0.001. Other variables including RNA qual-
ity, heavy drug use, heavy alcohol use, gender and suicide
affected the expression levels in the range of 0.5-1%.
For the analysis of typical AP and atypical AP effects, eight
confounding variables (refrigerator time, PMI, rate of
death, mRNA quality, heavy drug use, heavy alcohol use,
gender and suicide) were adjusted on a gene-by-gene level
with multiple regression models in order to compute
adjusted p-values and fold changes. Among these varia-
bles, suicide was a schizophrenia-specific variable and
Table 1: A summary of subject characteristics.
Unaffected Control Typical AP Atypical AP
No. of Subjects 34 24 26
Age 45.9 ± 1.8 47.1 ± 2.2 42.8 ± 2.4
Gender (Male) 73% 63% 65%
Race (White) 94% 92% 89%
pH 6.4 ± 0.1 6.4 ± 0.1 6.5 ± 0.1
PMI 27.2 ± 2.5 36.3 ± 3.7 37.1 ± 4.7
BMI 29.2 ± 1.5 29.6 ± 1.3 30.5 ± 1.5
Heavy Drug Use 9% 9% 12%
Heavy Alcohol Use 9% 14% 8%
Suicide 0% 24% 27%
PMI: postmortem interval, BMI: body mass indexBMC Psychiatry 2009, 9:57 http://www.biomedcentral.com/1471-244X/9/57
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Individual demographic and clinical variable analyses Figure 1
Individual demographic and clinical variable analyses. Three variables including refrigerator time, PMI and rate of death 
affected more than 1% of the transcripts in the liver (fold change >1.3 and p < 0.001). Other variables such as mRNA quality, 
heavy drug use, heavy alcohol use, gender and suicide status affected the expression levels in the range of 0.5-1%.
Table 2: A summary of fold changes and p-values for the transcripts (p < 0.01) in comparison between the typical AP vs. the controls, 
the atypical AP vs. the controls, and the typical AP vs. the atypical AP.
Fold change P-value
<1e-04 1e-04-0.001 0.001-0.01
Typical Atypical T vs. AT Typical Atypical T vs. AT Typical Atypical T vs. AT
1-1.5 19 7 9 124 46 67 607 371 518
1.5 - 2 69 4 11 111 14 56 212 55 200
2-2.5 31 3 1 22 0 12 28 5 24
>2.5 35 0 0 15 1 4 12 1 13
Total 154 14 21 272 61 139 859 432 755
Cumulative Total 154 14 21 426 75 160 1285 507 915
FDR (%) 1 14 10 4 24 11 14 35 19
Typical: Typical AP group vs. control group; Atypical: Atypical AP group vs. control group; T vs. AT: Typical AP group vs. atypical AP group; FDR: 
false discovery rateBMC Psychiatry 2009, 9:57 http://www.biomedcentral.com/1471-244X/9/57
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thus, this variable was adjusted only in the schizophrenia
subjects (typical AP and atypical AP groups). Table 2
shows a summary of fold change (FC) and p-values for the
genes in each comparison including the typical AP vs. the
controls, the atypical AP vs. the controls, and the typical
AP vs. the atypical AP. The comparison between the typi-
cal AP and the control group revealed 426 transcripts (p <
0.001 and FDR of 4%). Among the 426 transcripts, 103
transcripts showed FC >2, indicating robust effects of typ-
ical APs on gene expression in the liver. The comparison
between the atypical AP and the control group revealed 75
transcripts (p < 0.001 and FDR of 24%). Among the 75
transcripts, only 4 transcripts show FC >2, indicating
modest effects of atypical APs compared to typical APs.
The comparison between the typical APs and the atypical
APs revealed 160 transcripts (p < 0.001 and FDR of 11%)
and 17 transcripts showed FC >2. See Additional Files 1, 2
and 3 for a list of significant transcripts (FC>1.3 and p <
0.001) in each comparison.
Following the gene-level analysis, we examined the bio-
logical functions of these genes using the DAVID func-
tional annotation. Table 3 shows the biological functions
overrepresented in each comparison. For example, genes
associated with nuclear protein (p = 3.75E-07), response
to stress (p = 4.49E-06) and phosphorylation (p = 1.13E-
05) are overrepresented in the comparison between the
typical AP and the controls. Genes associated with golgi/
endoplasmic reticulum (p = 6.19E-08) and transport
function (p = 2.86E-07) are overrepresented in the com-
parison between the atypical AP and the controls. A com-
parison between the typical AP and the atypical AP further
identified the genes associated with lipid metabolism (p =
9.59E-05), membrane-bound organelle (p = 3.03E-04)
and mitochondrion (p = 3.66E-04).
We identified a set of genes significantly associated with
specific biological function from the functional annota-
tion. For instance, genes associated with the nuclear pro-
tein (FC>1.3 and p < 0.001) were differentially expressed
in the typical AP group compared to the controls (Figure
2). Individual genes with fold changes and 95% confi-
dence intervals show that approximately half of the genes
are up-regulated and the other half are down-regulated in
the nuclear protein category. These genes include many
transcription factors and DNA binding proteins that are
critical for regulating a cascade of gene expression events
in the nucleus of cells.
Figure 3 illustrates the genes associated with the golgi/
endoplasmic reticulum are consistently up-regulated in
the atypical AP group compared to the controls. However,
most of the genes show moderate fold changes between
1.3 and 2 compared to the fold changes observed between
the typical AP group and the controls. Increased gene
expression associated with the golgi/endoplasmic reticu-
lum suggest that atypical APs affect post-translational
modifications, rather than the genes involved in direct
transcriptional modifications in the nucleus of the cells.
Figure 4 shows the genes associated with the lipid metab-
olism are consistently down-regulated in the typical AP
group compared to the atypical AP group. Two CYP450
isozymes, CYP7A1 and CYP51A1, also show down-regu-
lation in the typical AP group as compared to the atypical
AP group. Differential effects of typical APs and atypical
APs on lipid biosynthesis and metabolism may provide
further evidences for the metabolism-related syndrome
that has been observed with atypical APs [18,19,31,32].
Table 3: Significant biological terms in each comparison between typical AP vs. control, atypical AP vs. control, and typical AP vs. 
atypical AP. 
Comparison Category Term Count % P-Value
Typical vs. Ctrl SP_PIR_KEYWORDS Nuclear protein 70 21% 3.75E-07
Typical vs. Ctrl GOTERM_BP_ALL Response to stress 39 12% 4.49E-06
Typical vs. Ctrl SP_PIR_KEYWORDS Phosphorylation 46 14% 1.13E-05
Typical vs. Ctrl INTERPRO_NAME Basic-leucine zipper (bZIP) transcription factor 8 2% 1.46E-05
Typical vs. Ctrl GOTERM_MF_ALL Protein binding 97 29% 1.56E-05
Atypical vs. Ctrl SP_PIR_KEYWORDS ER-golgi transport 6 11% 6.19E-08
Atypical vs. Ctrl GOTERM_CC_ALL Cytoplasm 26 46% 7.84E-08
Atypical vs. Ctrl GOTERM_BP_ALL ER to Golgi vesicle-mediated transport 6 11% 2.86E-07
Atypical vs. Ctrl SP_PIR_KEYWORDS Endoplasmic reticulum 9 16% 1.96E-06
Atypical vs. Ctrl GOTERM_BP_ALL Golgi vesicle transport 6 11% 2.12E-06
Typical vs. Atypical GOTERM_BP_ALL Cellular lipid metabolism 13 10% 9.59E-05
Typical vs. Atypical GOTERM_BP_ALL Lipid biosynthesis 9 7% 1.14E-04
Typical vs. Atypical GOTERM_BP_ALL Lipid metabolism 14 10% 2.34E-04
Typical vs. Atypical GOTERM_CC_ALL Intracellular membrane-bound organelle 54 40% 3.03E-04
Typical vs. Atypical GOTERM_CC_ALL Mitochondrion 14 10% 3.66E-04
A set of significant genes (FC>1.3 and p < 0.001) in each comparison was used in the DAVID functional annotation analyses.BMC Psychiatry 2009, 9:57 http://www.biomedcentral.com/1471-244X/9/57
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Following the AP class analyses, we analyzed individual
AP drug effects on gene expression in the liver. Individual
AP drug analysis including haloperidol, phenothiazines,
olanzapine, risperidone and the unaffected controls
revealed 158 transcripts (FDR p < 0.05) that are differen-
tially regulated among the four AP drug groups. We then
compared this result with the previous results from AP
class comparisons (typical AP vs. control and atypical AP
vs. control). Among the 158 transcripts, we identified 151
transcripts that are common in the typical AP class com-
parison and 20 transcripts that are common in the atypi-
cal AP class comparison. This confirms that typical APs,
not atypical APs, exert robust effects on gene expression in
the liver. Among those 151 transcripts, 26 transcripts are
associated with response to stress based on the functional
annotation analysis (adj. p = 0.001, fold enrichment =
3.21). Figure 5 illustrates four example genes that are dif-
ferentially regulated by individual AP drugs. For instance,
C-reactive protein (CRP) expression (FDR p = 0.0002)
and interleukin receptor 1 antagonist (IL1RN) expression
(FDR p = 0.0004) are selectively increased by the pheno-
thiazines. In contrast, transglutaminase 2 (TGM2) expres-
sion is increased by all four AP drugs as compared to the
controls (FDR p < 0.0001). A catalase (CAT) gene expres-
sion is decreased by phenothiazines, haloperidol, and
olanzapine, but not by risperidone (FDR p < 0.01).
Detailed information on the 151 genes is shown in Addi-
tional File 4.
Following the microarray analysis, we performed quanti-
tative PCR to validate a set of genes that are differentially
expressed between the typical AP and the atypical AP
groups. Figure 6 demonstrates that 5 genes, CYP7A1,
CEBPA, AR1, ABCG5 and CYP51A1, are down-regulated
and 3 genes, FOSL2, SOD2 and IL1RN, are up-regulated in
the typical AP group compared to the atypical AP group.
The magnitude of the fold changes are similar to the fold
changes observed in the microarray data analysis, con-
firming the consistency between these two different gene
expression assays.
Genes associated with the nuclear protein function are differentially regulated in the typical AP group compared to the control  group Figure 2
Genes associated with the nuclear protein function are differentially regulated in the typical AP group com-
pared to the control group. Each gene is plotted with fold change and 95% confidence intervals. Green: p < 0.001 and red: 
p < 0.0001BMC Psychiatry 2009, 9:57 http://www.biomedcentral.com/1471-244X/9/57
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Discussion
It is well accepted that typical APs and atypical APs medi-
ate differential therapeutic and side effects in individuals
who are taking AP medications. Most previous studies
have focused on the effects of typical APs and atypical APs
on gene expression and on drug metabolism using animal
models. Recent studies have investigated the effects of the
APs in the postmortem brains using gene expression
microarrays [33,34]. However, to our knowledge, none
has reported the effects of APs on global gene expression
profiles in the postmortem liver of schizophrenia
patients. Based on the previous studies on liver function,
it is likely that atypical APs have fewer side effects and less
liver toxicity than typical APs [35,36] and these differ-
ences may be partially due to the differential gene expres-
sion pattern induced by two different classes of AP drugs.
Effects of typical antipsychotics on gene expression
We found that typical APs affected the genes associated
with nuclear protein, response to stress and phosphoryla-
tion in the liver (Table 3). The genes associated with
nuclear protein include many transcription factors and
DNA binding proteins that are crucial to regulating
expression of other genes in the nucleus of cells. The typi-
cal AP haloperidol has been shown to induce DNA meth-
ylation changes in the brain and peripheral tissue of rats
[37]. Another typical APs phenothiazines may contribute
to liver toxicity [23], extrapyramidal side effects [38] and
chromosomal DNA damage [39]. Thus, these studies sug-
gest that typical APs may regulate biological functions
related to nuclear protein and stress responses in the liver
of schizophrenia patients.
Effects of atypical antipsychotics on gene expression
In contrast, atypical APs affected genes associated with the
golgi apparatus/endoplasmic reticulum in the liver. The
genes associated with this category were consistently up-
regulated, suggesting that atypical APs may regulate trans-
port mechanisms in the cytoplasm rather than affecting
gene expression cascades in the nucleus of cells. We found
that the genes associated with cytoplasmic function are
up-regulated in the atypical AP group (Additional file 5).
Genes associated with the golgi/endoplasmic reticulum transport are up-regulated in the atypical AP group compared to the  control group Figure 3
Genes associated with the golgi/endoplasmic reticulum transport are up-regulated in the atypical AP group 
compared to the control group. Each gene is plotted with fold change and 95% confidence intervals. Green: p < 0.001 and 
red: p < 0.0001BMC Psychiatry 2009, 9:57 http://www.biomedcentral.com/1471-244X/9/57
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Previous animal studies reported that chronic administra-
tion of atypical APs, in contrast to typical APs, does not
cause toxic effects in the liver [40]. However, the atypical
AP clozapine does induce a metabolic syndrome includ-
ing weight gain, glucose tolerance and insulin sensitivity
via alteration of glucose metabolism in rats [41]. Our
results suggest that there are clear differences between the
typical APs and the atypical APs on gene expression pro-
files in the liver of schizophrenia patients, consistent with
the previous animal studies [19,42].
Comparison between typical antipsychotics and atypical 
antipsychotics
Comparison between the typical APs and the atypical APs
revealed that genes associated with lipid metabolism and
biosynthesis are differentially regulated. Two CYP450 iso-
zyme genes, CYP51A1 and CYP7A1, were down-regulated
and these changes were confirmed by the qPCR. Although
previous studies reported the significance of CYP450 sys-
tems in AP drug metabolism, the role of these two iso-
zymes have not been reported. The significance of the
metabolic syndrome in schizophrenia, particularly the
potential side effects of atypical APs on lipid metabolism,
has been described previously [43,44]. For example, the
typical AP drug haloperidol reduced expression of
CYP450 genes in the liver of rats [45]. Many APs are
metabolized by the CYP450 isozymes and also the
enzyme activities are also regulated by the APs [46,47].
Therefore, a subset of CYP450 isozymes may have differ-
ent responses to typical APs or atypical APs in the liver of
schizophrenia patients.
Another biological function between the typical APs and
the atypical APs was mitochondrial function with 11
genes down-regulated and 3 genes up-regulated (Addi-
tional file 6). A study reported mitochondrial dysfunction
in schizophrenia [48] and mitochondrial genes may also
be affected by AP medication. For example, the APs
induced changes in mitochondria-related genes in post-
mortem brains of schizophrenia [49]. The authors sug-
gested that this was a medication effect rather than the
disease itself because the brains of AP-free schizophrenia
cases did not show similar effects on the mitochondrial
genes. Moreover, typical and atypical AP drugs exert differ-
Genes associated with the lipid metabolism are down-regulated in the typical AP group compared to the atypical AP group Figure 4
Genes associated with the lipid metabolism are down-regulated in the typical AP group compared to the atyp-
ical AP group. Each gene is plotted with fold change and 95% confidence intervals. Green: p < 0.001 and red: p < 0.0001BMC Psychiatry 2009, 9:57 http://www.biomedcentral.com/1471-244X/9/57
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ent effects on mitochondrial function in the rat liver and
these differences may provide a possible link to extrapy-
ramidal symptoms observed in patients taking typical APs
[50]. The typical AP, thioridazine, also interacts with the
inner membrane of mitochondria, acquiring antioxidant
activity toward processes with potential implications in
apoptosis [51]. Taken together, these results suggest that
APs affect the genes associated with mitochondrial func-
tion in the brain and in the liver.
There were 20 genes common between two comparisons
(typical AP vs. control and atypical AP vs. control) based
on the significance criteria (FC>1.3 and p < 0.001). These
genes include enzymes such as transglutaminase 2
(TGM2), nicotinamide N-methyltransferase (NNMT),
and inositol(myo)-1(or 4)-monophosphatase 2 (IMPA2).
Therefore, these enzymes may be involved in common
metabolic pathways affected by both typical AP and atyp-
ical AP classes in the liver of schizophrenia patients.
Although we only investigated gene expression profiles in
the liver, it is possible that these genes may be affected by
both typical APs and atypical APs in other tissues. Since
both typical AP and atypical AP drugs improve positive
symptoms of schizophrenia [18], the common genes
found between two comparisons may provide clues to
similar therapeutic and side effect profiles.
Effects of individual antipsychotic drugs on gene 
expression
Based on individual AP drug comparisons, we identified
158 transcripts that are differentially expressed among
four AP drugs (FDR adjusted p < 0.05). Among the four AP
drugs compared, the phenothiazines affected most of the
genes, and a subset of those genes (n = 26) were associated
with stress responses (adjusted p = 0.001, fold enrichment
= 3.21). This indicates that phenothiazines (chlorpro-
mazine, fluphenazine and thioridazine) with similar
chemical structure produce robust effects on gene expres-
Effects of individual AP drugs on gene expression are shown with fold change and 95% confidence intervals Figure 5
Effects of individual AP drugs on gene expression are shown with fold change and 95% confidence intervals. 
These genes show differential expression profiles in the liver by the individual AP drugs. Values are expressed as fold changes 
compared to the unaffected controls. Red: significant from the controls (FDR p < 0.05). RIS, risperidone; PHE, phenothiazines; 
OLA, olanzapine; HAL, haloperidol.BMC Psychiatry 2009, 9:57 http://www.biomedcentral.com/1471-244X/9/57
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sion that could contribute to liver toxicity [23], extrapy-
ramidal side effects [38] and even chromosomal DNA
damage [39] observed with phenothiazines. For instance,
we found that expression of C-reactive protein (CRP), a
marker of inflammation, was dramatically increased by
the phenothiazines (FC 21, FDR-adjusted p = 0.0002).
This corroborates a recent study that reported serum CRP
levels are increased more in schizophrenia patients who
had taken typical APs as compared to those who had
taken atypical APs [52]. This also suggests that the pheno-
thiazines affect the immune system and may cause oxida-
tive stress in the peripheral tissues.
qPCR validation
Quantitative PCR has become a standard for validating
gene expression changes identified in microarray studies
[53,54]. We selected a set of genes differentially expressed
between the typical AP and the atypical AP classes, and
validated the gene expression using qPCR. The CCAAT/
enhancer binding protein alpha (CEBPA) gene encodes a
basic leucine zipper motif (bZIP) transcription factor that
binds to the promoter and modulates the expression of
the leptin gene, a protein that plays an important role in
body weight homeostasis. The typical AP chlorpromazine
has been shown to increase insulin sensitivity in the liver
by attenuating insulin and leptin signaling pathways [55].
It is interesting that one of the main side effects of atypical
The qPCR validation of genes differentially expressed between the typical AP group and the atypical AP group based on the  microarray data analysis Figure 6
The qPCR validation of genes differentially expressed between the typical AP group and the atypical AP group 
based on the microarray data analysis. Normalized values for each gene in the typical AP group were expressed as fold 
change as compared to the atypical AP group. Each gene is shown with fold change and 95% confidence intervals.BMC Psychiatry 2009, 9:57 http://www.biomedcentral.com/1471-244X/9/57
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APs is weight gain and dysfunction of the CEBPA gene
may contribute to this side effect. The ATP-binding cas-
sette (ABCG5) gene is a member of the superfamily of
ATP-binding cassette (ABC) transporters. ABC proteins
transport various molecules across extra- and intra-cellu-
lar membranes and are expressed in liver tissue. Polymor-
phisms in the ABC gene are associated with treatment
resistance in schizophrenia and response to the atypical
AP drug risperidone in schizophrenia [56,57]. These stud-
ies suggest that the ABC genes may play a role in responses
to different APs in schizophrenia.
Among the up-regulated genes, FOS-like antigen 2
(FOSL2) encodes leucine zipper proteins that can dimer-
ize with proteins of the JUN family, thereby forming the
transcription factor complex AP-1. Chronic treatment
with APs induces long-lasting expression of the FOS and
JUN family genes and AP-1 complex in the rat prefrontal
cortex [58]. Although APs have been shown to regulate
the expression of FOS and JUN family genes in the rat
brain [58-60], the effect of typical APs and atypical APs on
these genes in the liver have not been reported. The super-
oxide dismutase 2 (SOD2) gene encodes a mitochondrial
protein that forms a homotetramer and binds one manga-
nese ion per subunit. The functions of the SOD2 protein
include binding to the superoxide byproducts of oxidative
phosphorylation and converting them to hydrogen perox-
ide and diatomic oxygen. While chronic administration of
the typical AP chlorpromazine decreases SOD enzyme
activity in the brain and in erythrocytes [61], the effects in
the liver are not known. The interleukin 1 receptor antag-
onist (IL1RN) gene inhibits the activities of interleukin 1,
and modulates a variety of interleukin 1-related immune
and inflammatory responses. Genes associated with the
immune and inflammatory responses have been reported
in schizophrenia [62,63]. Functional polymorphisms in
the interleukin genes have been reported in schizophrenia
[64] and therefore, interleukin genes may be promising
candidates for research in schizophrenia.
Strength of the current study
It is well known that gene expression studies using post-
mortem tissues of psychiatric patients are challenging [65-
68]. Disease-specific effects are often hindered by issues
such as relatively small sample size, small effect size and
heterogeneity of symptoms in the patient population
[69]. Also, clinical information available on each patient
is often incomplete, and so unknown clinical covariates
may either confound or confuse many of the gene expres-
sion findings [26,28]. Therefore, appropriate statistical
adjustment using available information is critical in order
to improve inferences in determining candidate genes and
the biology behind psychiatric disorders. However, most
previous studies have not accounted for these issues or
made adequate adjustments using appropriate statistical
methods. In this study, we first analyzed the demographic
and clinical variables, in order to identify potential con-
founding effects on gene expression. We then performed
the multiple regression analyses to adjust the confound-
ing variables on a gene-by-gene level to obtain adjusted p-
values and fold changes for the analysis of AP medication
effects.
Previous studies reported that gene expression fold
changes between unaffected controls and psychiatric
patients are relatively small, and statistical significance is
relatively weak, especially after adjusting for multiple con-
founding variables [27]. Compared to the postmortem
brain tissues, we found that the gene expression changes
are quite robust in the postmortem liver tissues. This may
be due to the direct and profound effects of APs on gene
expression in the liver as compared to the confounding
medication and disease effects found in the brain. Also,
the robust effects observed in the liver may be due to the
cell-type homogeneity of the liver compared to the brain,
in which several cell types are present in any given region.
Limitations
Although the current study investigated the effects of AP
medications on gene expression profiles in the postmor-
tem liver of schizophrenia patients, caution is required
when interpreting the results. Clinical information availa-
ble from each patient is often incomplete and AP medica-
tion effects are confounded by heterogeneous medication
regimen. For instance, some patients had a mixed medica-
tion history with prescriptions for both typical and atypi-
cal AP drugs during the course of the illness. However, the
current analysis revealed that the typical AP class, not the
atypical AP class, exerts robust gene expression changes in
the liver of schizophrenia patients. In order to address
individual AP drug effects on gene expression, we sub-
classified the schizophrenia subjects into 4 AP groups
based on their recent medication history from one or two
years prior to death. Although it was not possible to
obtain complete medication history and information on
medication adherence from each patient, we attempted to
identify genes and biological functions that are affected by
those four AP drugs including phenothiazines, haloperi-
dol, olanzapine and risperidone in the liver. Due to the
limitations inherent to the postmortem tissues of psychi-
atric patients, the current study should be considered as
exploratory rather than conclusive. Further animal and
cell culture studies with controlled medication regimen
are necessary to extend the findings from the current
study.
Conclusion
Typical AP and atypical AP medication affect different
genes and biological functions in the liver of schizophre-
nia patients. The typical AP phenothiazines producedBMC Psychiatry 2009, 9:57 http://www.biomedcentral.com/1471-244X/9/57
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robust effects on gene expression and a subset of those
genes are associated with stress responses in the liver.
Thus, the genes and the pathways identified in the current
study may provide important clues to the differential ther-
apeutic and side effects mediated by two different classes
of APs. Moreover, the current findings may provide useful
information for developing novel APs with better thera-
peutic and side effect profiles.
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